Skip to main content

Table 1 Distribution of clinical characteristics by recreational physical activity category among the 1254 participants with any information on methylation (gene-specific and/or global) and lifetime physical activity in a population-based cohort of women diagnosed with first primary breast cancer, Long Island Breast Cancer Study Project

From: Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes

Recreational physical activity

Inactive

(n = 294)

<6.36 h/week

(n = 497)

≥6.36 h/week

(n = 463)

n (%)

n (%)

n (%)

Age at diagnosis

 <50 years

55 (18.71)

170 (34.21)

136 (29.37)

 ≥50 years

239 (81.29)

327 (65.79)

327 (70.63)

Menopausal status

 Premenopausal

55 (19.37)

187 (38.09)

148 (32.74)

 Postmenopausal

229 (80.63)

304 (61.91)

304 (67.26)

Family history of breast cancer

 No

225 (78.13)

396 (82.16)

361 (80.94)

 Yes

63 (21.88)

86 (17.84)

85 (19.06)

Body mass index (BMI)

 BMI <25 kg/m2

113 (38.97)

240 (48.58)

200 (43.67)

 BMI 25–29.9 kg/m2

92 (31.72)

157 (31.78)

157 (34.28)

 BMI ≥30 kg/m2

85 (29.31)

97 (19.64)

191 (22.05)

Cigarette smoking

 Never

138 (46.94)

231 (46.48)

199 (42.98)

 Current/former

156 (53.06)

266 (53.32)

264 (57.02)

History of benign breast disease

 No

248 (84.35)

393 (79.07)

370 (80.09)

 Yes

46 (15.65)

104 (20.93)

92 (19.91)

Cancer type

 In situ

39 (13.27)

97 (19.52)

57 (12.31)

 Invasive

255 (86.73)

400 (80.48)

406 (87.69)

Hormone receptor statusa

 Positive

158 (81.44)

252 (78.02)

260 (79.75)

 Negative

36 (18.35)

71 (21.98)

66 (20.25)

Estrogen receptor status

 Positive

147 (75.77)

235 (72.76)

248 (76.07)

 Negative

47 (24.23)

88 (27.24)

78 (23.93)

Progesterone receptor status

 Positive

125 (64.43)

203 (62.85)

220 (67.48)

 Negative

69 (35.57)

120 (37.15)

106 (32.52)

Tumor size

 <2 cm

94 (60.26)

171 (66.28)

187 (68.75)

 ≥2 cm

62 (39.74)

87 (33.72)

85 (31.25)

Nodal involvement

 0

45 (27.78)

73 (27.76)

48 (18.05)

 1

117 (72.22)

190 (72.24)

218 (81.95)

Treatment type

 No chemotherapy

120 (65.57)

206 (56.59)

183 (60.00)

 Chemotherapy

63 (34.43)

158 (43.41)

122 (40.00)

 No radiation

75 (40.98)

148 (40.55)

113 (36.81)

 Radiation

108 (59.02)

217 (59.45)

194 (63.19)

 No hormone therapy

58 (32.22)

144 (40.11)

119 (39.40)

 Hormone therapy

122 (67.78)

215 (59.89)

183 (60.60)

  1. a Any estrogen receptor-positive or progesterone receptor-positive tumor